The Urokinase Plasminogen Activator System: Role in Malignancy

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|10|1|39-49

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.10, Iss.1, 2004-01, pp. : 39-49

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New developments in the urokinase-type plasminogen activator system

By Rosenberg Steven  

Expert Opinion on Therapeutic Targets, Vol. 5, Iss. 6, 2001-12 ,pp. : 711-722

Informa Healthcare

Access to resources Recommend Favorite

Emerging therapeutic targets in oncology: urokinase-type plasminogen activator system

By Magill C.   Katz B.A.   Mackman R.L.  

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 1, 1999-03 ,pp. : 109-133

Informa Healthcare

Access to resources Recommend Favorite

The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy

By  

Current Cancer Drug Targets, Vol. 9, Iss. 1, 2009-02 ,pp. : 32-71

Bentham Science Publishers

Access to resources Recommend Favorite

Preface The Urokinase-type Plasminogen Activator System in Cancer and other Pathological Conditions: Introduction and Perspective [Hot Topic: The Urokinase-type Plasminogen Activator System in Cancer (Executive Editor : S. Rosenberg)].

By  

Current Pharmaceutical Design, Vol. 9, Iss. 19, 2003-07 ,pp. : iv-iv

Bentham Science Publishers

Access to resources Recommend Favorite

Inhibitors of the Protease Domain of Urokinase-Type Plasminogen Activator

By  

Current Pharmaceutical Design, Vol. 8, Iss. 28, 2002-12 ,pp. : 2541-2558

Bentham Science Publishers

Access to resources Recommend Favorite